Search Articles — Sudonull

https://sudonull.com/china-approved-the-first-invasive-brain-implant-neo-a-bci-breakthrough

China became the first in the world to approve the invasive NEO chip for brain-computer interface (BCI). Analysis of the regulatory race, risks, market, and forecasts. Find out who won.

https://sudonull.com/china-approved-invasive-brain-implant-neo-first-in-the-world

China became the first in the world to approve commercial use of the invasive brain implant NEO. Paralyzed patients can move their hands again. Learn how BCI is changing neurotechnology.

https://sudonull.com/china-launched-the-first-supercritical-co2-power-plant-risks-and-prospects

China has commissioned the world's first 30 MW supercritical CO₂ power plant. We analyze engineering risks, corrosion, industrial benefits, and the global context. Find out why this is the 'hydrogen moment' of energy.

https://sudonull.com/renewable-energy-sources-overtake-gas-for-the-first-time-analysis-of-the-2026-record

In April 2026, solar and wind overtook gas in electricity generation. But this victory comes amid a crisis. Read a detailed analysis of Ember data and forecasts.

https://sudonull.com/quantum-computer-alice-bob-helium-the-first-upgradable

French startup Alice & Bob has released Helium, the first upgradable quantum computer with cat qubits. Learn how 18 qubits are changing the quantum race and challenging IBM.

https://ymaho.com/beauty-trends-spring-summer-2026-naturalness-and-light-chic

Naturalness and light chic: bronté blush, brows without lamination, 90s part. Analysis of seasonal trends and the hidden economy of the beauty industry. Learn more.

https://ymaho.com/vepdegestrant-the-first-breast-cancer-protein-degrader

FDA approved vepdegestrant — the first PROTAC degrader for breast cancer with ESR1 mutation. Learn how it destroys resistance and what will change in therapy. Details here.

https://ymaho.com/ema-approved-the-first-therapy-for-pros-analysis-of-vijoice

Despite the failure of the confirmatory study, EMA approved alpelisib for severe PROS syndrome. We analyze the mechanism, risks, and prospects of Vijoice.

https://ymaho.com/fda-approved-the-first-gene-therapy-for-hereditary-deafness

Regeneron's Otarmeni restores hearing to normal in 42% of patients. The therapy treats OTOF gene mutations with a single injection. Learn how AAV vector technology has for the first time restored the ability to hear a whisper.

https://lrivo.com/arsenal-is-the-first-finalist-of-the-2025-2026-champions-league

Bukayo Saka brought Arsenal a victory over Atlético (1:0) and a place in the Champions League final. Learn the details of the historic match at the Emirates.

https://ymaho.com/beauty-pie-at-liberty-the-brand-s-first-offline-corner

Marcia Kilgore launches the first physical Beauty Pie corner in London. Learn how the retail test is changing the game for DTC brands. Read the details.

https://ymaho.com/vepdegestrant-fda-approved-the-first-protac-degrader

FDA approved Vepdegestrant — the first protein degrader tablet for ESR1-mutant breast cancer. PFS 5 months vs 2.1 for fulvestrant. Learn why this is a paradigm shift.

https://ymaho.com/ema-approved-jascayd-the-first-drug-for-the-treatment-of-pulmonary-fibrosis

EMA has approved for the first time Jascayd (nerandomilast) for the treatment of idiopathic and progressive pulmonary fibrosis. Advantage of 68.8 mL, mortality reduction of 43%. Learn about the breakthrough in pulmonology.

https://ymaho.com/ema-approved-the-first-oral-glp-1-drug-wegovy-for-weight-control

EMA recommended the first GLP-1 tablet for weight loss — Wegovy (semaglutide) 25 mg. Efficacy up to 16.6% weight loss. Market analysis, winners and losers. Learn more.

https://ymaho.com/ema-recommended-the-first-oral-glp-1-drug-for-weight-loss-wegovy

EMA issued a positive opinion on the first oral GLP-1 Wegovy for weight loss. Analysis of efficacy, price, side effects and market forecast. Read details.